Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

OTHER 1

Study Type

Interventional 16Observational 1Expanded_access 1

Sponsor

Cancer Type

Endocrine 2Head & Neck 1CNS 1

Conditions

Thyroid cancer, medullary 1Pheochromocytoma 1Paraganglioma 1Neuroblastoma 1Insulinoma 1Carcinoid Tumor 1

Interventions

3-Iodobenzylguanidine 9TIC10 compound 3vorasidenib 1ulixertinib 1tucatinib 1tovorafenib 1rindopepimut 1pembrolizumab 1pegfilgrastim 1paclitaxel-Angiopep-2 conjugate 1omburtamab I-131 1mogamulizumab 1mirdametinib 1gallium maltolate 1fluorodopa F 18 1efineptakin alfa 1carbon-11 methionine 1avapritinib 1Vorinostat 1Vaccination 1Proton Pump Inhibitors 1Potassium Iodide 1OKN 007 1Methionine 1Ketoconazole 1Ipilimumab 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Fenretinide 1Eflornithine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × fluorodopa F 18 × CNS × Clear all
NCT02431715 2023-02-21

18F-FDOPA PET in Neuroendocrine Tumours

British Columbia Cancer Agency

No longer available
CNSEndocrineHead & Neck

Thyroid cancer, medullary, Carcinoid Tumor, Insulinoma, Neuroblastoma, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡